In our prior report [1], we confirmed that prophylactic administration of G-CSF was associated with significant reductions in the incidence of overall neutropenia events (41.1% vs 76.6%, p < 0.001) and febrile neutropenia (10.1% vs 16.0%, p = 0.032) of any grade compared with patients who did not receive G-CSF. This evidence concerns the gene CSF3 and Decreased total neutrophil count.